Search

Your search keyword '"Hasselbalch, Hans C."' showing total 283 results
Start Over Author "Hasselbalch, Hans C."
283 results on '"Hasselbalch, Hans C."'

2. Response to pegylated interferon in a COVID‐19–positive elderly woman with primary myelofibrosis treated with ruxolitinib

Author

Frankel, Arthur E, Reddy, Renuka, DeSuza, Kayla R, Deeb, Khaled, Carlin, Aaron F, Smith, Davey, Xie, Yushuang, Naik, Eknath, Silver, Richard T, and Hasselbalch, Hans C

Subjects
Emerging Infectious Diseases, Vaccine Related, Infectious Diseases, Genetics, Infection, Good Health and Well Being, COVID‐19, interferon, ruxolitinib
Abstract

An 83-year-old female had asymptomatic SARS-CoV-2 infection while taking ruxolitinib. She remained RT-PCR positive for viral RNA for >120 days, and Pegylated interferon for 4 weeks led to viral RNA clearance. The observations support combination therapy of ruxolitinib + interferon for COVID-19.

Published
2021

3. Mathematical modelling of stem and progenitor cell dynamics during ruxolitinib treatment of patients with myeloproliferative neoplasms

Author

Boklund, Tobias Idor, primary, Snyder, Jordan, additional, Gudmand-Hoeyer, Johanne, additional, Larsen, Morten Kranker, additional, Knudsen, Trine Alma, additional, Eickhardt-Dalbøge, Christina Schjellerup, additional, Skov, Vibe, additional, Kjær, Lasse, additional, Hasselbalch, Hans C., additional, Andersen, Morten, additional, Ottesen, Johnny T., additional, and Stiehl, Thomas, additional

Published
2024
Full Text
View/download PDF

6. Mathematical modelling of stem and progenitor cell dynamics during ruxolitinib treatment of patients with myeloproliferative neoplasms.

Author

Idor Boklund, Tobias, Snyder, Jordan, Gudmand-Hoeyer, Johanne, Kranker Larsen, Morten, Knudsen, Trine Alma, Schjellerup Eickhardt-Dalbøge, Christina, Skov, Vibe, Kjær, Lasse, Hasselbalch, Hans C., Andersen, Morten, Ottesen, Johnny T., and Stiehl, Thomas

Subjects
PROGENITOR cells, MYELOPROLIFERATIVE neoplasms, STEM cells, RUXOLITINIB, STANDARD deviations
Abstract

Introduction: The Philadelphia chromosome-negative myeloproliferative neoplasms are a group of slowly progressing haematological malignancies primarily characterised by an overproduction of myeloid blood cells. Patients are treated with various drugs, including the JAK1/2 inhibitor ruxolitinib. Mathematical modelling can help propose and test hypotheses of how the treatment works. Materials and methods: We present an extension of the Cancitis model, which describes the development of myeloproliferative neoplasms and their interactions with inflammation, that explicitly models progenitor cells and can account for treatment with ruxolitinib through effects on the malignant stem cell response to cytokine signalling and the death rate of malignant progenitor cells. The model has been fitted to individual patients' data for the JAK2 V617F variant allele frequency from the COMFORT-II and RESPONSE studies for patients who had substantial reductions (20 percentage points or 90% of the baseline value) in their JAK2 V617F variant allele frequency (n = 24 in total). Results: The model fits very well to the patient data with an average root mean square error of 0.0249 (2.49%) when allowing ruxolitinib treatment to affect both malignant stem and progenitor cells. This average root mean square error is much lower than if allowing ruxolitinib treatment to affect only malignant stem or only malignant progenitor cells (average root mean square errors of 0.138 (13.8%) and 0.0874 (8.74%), respectively). Discussion: Systematic simulation studies and fitting of the model to the patient data suggest that an initial reduction of the malignant cell burden followed by a monotonic increase can be recapitulated by the model assuming that ruxolitinib affects only the death rate of malignant progenitor cells. For patients exhibiting a long-term reduction of the malignant cells, the model predicts that ruxolitinib also affects stem cell parameters, such as the malignant stem cells' response to cytokine signalling. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

8. Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study

Author

Bauer, Franz, Berbec, Nicoleta, Besses Raebel, Carlos, Borbenyi, Zita, Bumbea, Horia, Buxhofer-Ausch, Veronika, Calbecka, Malgorzata, Cayssials-Caylus, Emilie, Cazzola, Mario, Cerna, Olga, Cucuianu, Andrei, Dima, Delia Monica, Forjan, Ernst, Gheorghita, Emanuil, Greil, Richard, Hatalova, Antonia, Hrubisko, Mikulas, Jakucs, Janos, Kaplan, Polina, Klymenko, Sergiy, Koschmieder, Steffen, Lazaroiu, Mihaela, Lysa, Tamila, Masliak, Zvenyslava, Masszi, Tamas, Mihaylov, Georgi, Myasnikov, Alexander, Platzbecker, Uwe, Puyade, Mathieu, Rey, Jerome, Roy, Lydia, Schwarz, Jiri, Skotnicki, Aleksander, Sokolova, Irina, Soroka-Wojtaszko, Maria, Starzak-Gwozdz, Jolanta, Stoeva, Vera, Torregrosa-Diaz, Jose Miguel, Vallova, Anna, Volodicheva, Elena, Warzocha, Krzysztof, Willenbacher, Ella, Wolf, Dominik, Gisslinger, Heinz, Klade, Christoph, Georgiev, Pencho, Krochmalczyk, Dorota, Gercheva-Kyuchukova, Liana, Egyed, Miklos, Rossiev, Viktor, Dulicek, Petr, Illes, Arpad, Pylypenko, Halyna, Sivcheva, Lylia, Mayer, Jiri, Yablokova, Vera, Krejcy, Kurt, Grohmann-Izay, Barbara, Hasselbalch, Hans C, Kralovics, Robert, and Kiladjian, Jean-Jacques

Published
2020
Full Text
View/download PDF

12. P1034: FROM SNAPSHOT TO CONTINUUM: CUMULATIVE TIME IN RESPONSE AS AN EMERGING PROXY FOR THROMBOTIC RISK IN POLYCYTHEMIA VERA

Author

Gisslinger, Heinz, primary, Klade, Christoph, additional, Georgiev, Pencho, additional, Krochmalczyk, Dorota, additional, Gercheva-Kyuchukova, Liana, additional, Egyed, Miklos, additional, Dulicek, Petr, additional, Illes, Arpad, additional, Pylypenko, Halyna, additional, Sivcheva, Lylia, additional, Mayer, Jiří, additional, Yablokova, Vera, additional, Krejcy, Kurt, additional, Empson, Victoria, additional, Hasselbalch, Hans C., additional, Kralovics, Robert, additional, and Kiladjian, Jean-Jacques, additional

Published
2023
Full Text
View/download PDF

13. JAK2V617F but not CALR mutations confer increased molecular responses to interferon-α via JAK1/STAT1 activation

Author

Czech, Julia, Cordua, Sabrina, Weinbergerova, Barbora, Baumeister, Julian, Crepcia, Assja, Han, Lijuan, Maié, Tiago, Costa, Ivan G., Denecke, Bernd, Maurer, Angela, Schubert, Claudia, Feldberg, Kristina, Gezer, Deniz, Brümmendorf, Tim H., Müller-Newen, Gerhard, Mayer, Jiri, Racil, Zdenek, Kubesova, Blanka, Knudsen, Trine, Sørensen, Anders L., Holmström, Morten, Kjær, Lasse, Skov, Vibe, Larsen, Thomas Stauffer, Hasselbalch, Hans C., Chatain, Nicolas, and Koschmieder, Steffen

Published
2019
Full Text
View/download PDF

15. Case Report: First longitudinal study of a patient with CALR positive clonal hematopoiesis of indeterminate potential developing into pre-fibrotic myelofibrosis

Author

Kjær, Lasse, primary, Skov, Vibe, additional, Larsen, Morten Kranker, additional, Boklund, Tobias Idor, additional, Andersen, Morten, additional, Kefala, Maria, additional, Knudsen, Trine A., additional, Schjellerup Eickhardt-Dalbøge, Christina, additional, Stiehl, Thomas, additional, Gudmand-Høyer, Johanne, additional, Snyder, Jordan, additional, Holmström, Morten, additional, Andersen, Mads H., additional, Ottesen, Johnny T., additional, Ellervik, Christina, additional, and Hasselbalch, Hans C., additional

Published
2023
Full Text
View/download PDF

20. A novel integrated biomarker index for the assessment of hematological responses in MPNs during treatment with hydroxyurea and interferon‐alpha2

Author

Dam, Marc J. B., primary, Pedersen, Rasmus K., additional, Knudsen, Trine A., additional, Andersen, Morten, additional, Ellervik, Christina, additional, Larsen, Morten Kranker, additional, Kjær, Lasse, additional, Skov, Vibe, additional, Hasselbalch, Hans C., additional, and Ottesen, Johnny T., additional

Published
2022
Full Text
View/download PDF

21. Clonal haematopoiesis of indeterminate potential and impaired kidney function—A Danish general population study with 11 years follow‐up

Author

Larsen, Morten K., primary, Skov, Vibe, additional, Kjær, Lasse, additional, Møller‐Palacino, Natascha A., additional, Pedersen, Rasmus K., additional, Andersen, Morten, additional, Ottesen, Johnny T., additional, Cordua, Sabrina, additional, Poulsen, Henrik E., additional, Dahl, Morten, additional, Knudsen, Trine A., additional, Eickhardt‐Dalbøge, Christina Schjellerup, additional, Koschmieder, Steffen, additional, Pedersen, Kasper M., additional, Çolak, Yunus, additional, Bojesen, Stig E., additional, Nordestgaard, Børge G., additional, Stiehl, Thomas, additional, Hasselbalch, Hans C., additional, and Ellervik, Christina, additional

Published
2022
Full Text
View/download PDF

24. HSC Niche Dynamics in Regeneration, Pre-malignancy, and Cancer: Insights From Mathematical Modeling.

Author

Pedersen, Rasmus Kristoffer, Andersen, Morten, Skov, Vibe, Kjær, Lasse, Hasselbalch, Hans C, Ottesen, Johnny T, and Stiehl, Thomas

Subjects
STEM cell niches, HEMATOPOIETIC stem cells, MATHEMATICAL models, REGENERATION (Biology), BONE marrow transplantation, BONE marrow
Abstract

The hematopoietic stem cell (HSC) niche is a crucial driver of regeneration and malignancy. Its interaction with hematopoietic and malignant stem cells is highly complex and direct experimental observations are challenging. We here develop a mathematical model which helps relate processes in the niche to measurable changes of stem and non-stem cell counts. HSC attached to the niche are assumed to be quiescent. After detachment HSC become activated and divide or differentiate. To maintain their stemness, the progeny originating from division must reattach to the niche. We use mouse data from literature to parametrize the model. By combining mathematical analysis and computer simulations, we systematically investigate the impact of stem cell proliferation, differentiation, niche attachment, and detachment on clinically relevant scenarios. These include bone marrow transplantation, clonal competition, and eradication of malignant cells. According to our model, sampling of blood or bulk marrow provides only limited information about cellular interactions in the niche and the clonal composition of the stem cell population. Furthermore, we investigate how interference with processes in the stem cell niche could help to increase the effect of low-dose chemotherapy or to improve the homing of genetically engineered cells. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

26. Clonal haematopoiesis of indeterminate potential and impaired kidney function - A Danish general population study with 11 years follow-up

Author

Larsen, Morten K., Skov, Vibe, Knudsen, Trine A., Eickhardt-Dalbøge, Christina Schjellerup, Koschmieder, Steffen, Pedersen, Kasper M., Çolak, Yunus, Bojesen, Stig E., Nordestgaard, Børge G., Stiehl, Thomas, Hasselbalch, Hans C., Ellervik, Christina, Kjaer, Lasse, Møller-Palacino, Natascha A., Pedersen, Rasmus K., Andersen, Morten, Ottesen, Johnny T., Cordua, Sabrina, Poulsen, Henrik E., and Dahl, Morten

Published
2022

28. A novel integrated biomarker index for the assessment of hematological responses in MPNs during treatment with hydroxyurea and interferon‐alpha2.

Author

Dam, Marc J. B., Pedersen, Rasmus K., Knudsen, Trine A., Andersen, Morten, Ellervik, Christina, Larsen, Morten Kranker, Kjær, Lasse, Skov, Vibe, Hasselbalch, Hans C., and Ottesen, Johnny T.

Subjects
BLOOD cell count, HYDROXYUREA, MYELOPROLIFERATIVE neoplasms, BIOMARKERS, PATIENTS' attitudes
Abstract

Background: Conventional cytoreductive therapy for patients with chronic Philadelphia‐negative myeloproliferative neoplasms (MPNs) includes hydroxyurea (HU), interferon‐alpha2 (IFN), and anagrelide. HU is worldwide the most used cytoreductive agent, which lowers elevated blood cell counts within days in the large majority of patients. However, some patients may experience rebound cytosis when HU is reduced due to cytopenia, thereby potentially giving rise to fluctuating cell counts during therapy. Such rapid oscillations may be harmful and potentially elicit thrombosis. Treatment with IFN gradually lowers elevated cell counts within weeks and when the dosage is reduced, the cell counts do not rapidly increase but are sustained within the normal range in the large majority of patients. Conventional hematological response criteria are among others based upon single absolute cell count values and do not take into account the relative decreases toward normal for each cell count. Materials, Methods & Results: Using serial data from the Danish DALIAH trial, we herein describe a novel integrated biomarker index for the assessment of hematological and molecular (JAK2V617F) responses in patients with MPNs during treatment with IFN or HU. Discussion: This novel tool convincingly displays the superiority of IFN versus HU in normalizing elevated cell counts. Our results need to be validated in larger studies but already now call for studies of the safety and efficacy of combination therapy during the initial treatment of patients with MPNs. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

31. The Impact of Somatic Mutations upon the Response to Combination Therapy with Ruxolitinib and Interferon in MPN Patients

Author

Skov, Vibe, primary, Sørensen, Anders Lindholm, additional, Knudsen, Trine Alma, additional, Bjørn, Mads Emil, additional, Ellervik, Christina, additional, Kranker Larsen, Morten, additional, Eickhardt-Dalbøge, Christina Schjellerup Schjellerup, additional, Christensen, Sarah Friis, additional, Thomassen, Mads, additional, Kruse, Torben A, additional, and Hasselbalch, Hans C., additional

Published
2021
Full Text
View/download PDF

32. Labor Market Attachment in Patients with Myeloproliferative Neoplasms: A Nationwide Matched Cohort Study

Author

Christensen, Sarah Friis, primary, Svingel, Lise Skovgaard, additional, Kjærsgaard, Anders, additional, Stenling, Anna, additional, Paulsson, Björn, additional, Andersen, Christen Lykkegaard, additional, Christiansen, Christian Fynbo, additional, Stentoft, Jesper, additional, Starklint, Jørn, additional, Severinsen, Marianne Tang, additional, Clausen, Mette Borg, additional, Hilsøe, Morten Hagemann, additional, Frederiksen, Henrik, additional, Hasselbalch, Hans C., additional, Bak, Marie, additional, and Mikkelsen, Ellen Margrethe, additional

Published
2021
Full Text
View/download PDF

33. Polycythemia Vera Patients Respond Better to Ropeginterferon Alfa-2b Than HU/BAT Irrespective of Pretreatment or Mutational Status; Results from 5 Years' Treatment in a Randomized, Controlled Setting in the PROUD-PV/Continuation-PV Trials

Author

Gisslinger, Heinz, primary, Klade, Christoph, additional, Georgiev, Pencho, additional, Krochmalczyk, Dorota, additional, Gercheva-Kyuchukova, Liana, additional, Egyed, Miklos, additional, Dulicek, Petr, additional, Illes, Arpad, additional, Pylypenko, Halyna, additional, Sivcheva, Lylia, additional, Mayer, Jiri, additional, Yablokova, Vera, additional, Krejcy, Kurt, additional, Empson, Victoria, additional, Hasselbalch, Hans C., additional, Kralovics, Robert, additional, and Kiladjian, Jean-Jacques, additional

Published
2021
Full Text
View/download PDF

34. The Gut Microbiota in Patients with Polycythemia Vera: Novel Vs. Conventional Treatments

Author

Eickhardt-Dalbøge, Christina Schjellerup Schjellerup, primary, Ingham, Anna Cäcilia, additional, Andersen, Lee O'Brien, additional, Nielsen, Henrik V, additional, Fuursted, Kurt, additional, Larsen, Morten Kranker, additional, Kjær, Lasse, additional, Christensen, Sarah Friis, additional, Knudsen, Trine Alma, additional, Skov, Vibe, additional, Ellervik, Christina, additional, Hasselbalch, Hans C., additional, Christensen, Jens Jørgen Elmer, additional, and Nielsen, Xiaohui Chen, additional

Published
2021
Full Text
View/download PDF

35. Data‐driven analysis of the kinetics of the JAK2V617F allele burden and blood cell counts during hydroxyurea treatment of patients with polycythemia vera, essential thrombocythemia, and primary myelofibrosis

Author

Dam, Marc J. B., primary, Pedersen, Rasmus K., additional, Knudsen, Trine A., additional, Andersen, Morten, additional, Skov, Vibe, additional, Kjær, Lasse, additional, Hasselbalch, Hans C., additional, and Ottesen, Johnny T., additional

Published
2021
Full Text
View/download PDF

42. MHC-I skewing in mutant calreticulin-positive myeloproliferative neoplasms is countered by heteroclitic peptide cancer vaccination

Author

Gigoux, Mathieu, Zappasodi, Roberta, Park, Joseph J, Pourpe, Stephane, Ghosh, Arnab, Bozkus, Cansu Cimen, Mangarin, Levi M.B., Redmond, David, Svena Verma, Svena, Sara Schad, Sara, Duke, William, Jan, Max, Leventhal, Matthew, Ho, Vincent, Gabriela Hobbs, Gabriela, Knudsen, Trine Alma, Skov, Vibe, Kjær, Lasse, Larsen, Thomas Stauffer, Lund Hansen, Dennis, Lindsley, R Coleman, Hasselbalch, Hans C., Grauslund, Jacob, Andersen, Mads, Holmström, Morten, Chan, Timothy, Rampal, Raajit, Abdel-Wahab, Omar, Nina Bhardwaj, Nina, Wolchok, Jedd D, Mullally, Ann, and Merghoub, Taha

Published
2020

46. Smoking, blood cells, and myeloproliferative neoplasms: meta-analysis and mendelian\ud randomization of 2.3 million people

Author

Jayasuriya, Nimesh A., Kjaergaard, Alisa D., Pedersen, Kasper M., Sorensen, Anders L., Bak, Marie, Larsen, Morten K., Nordestgaard, Borge G., Bojesen, Stig E., Colak, Yunus, Skov, Vibe, Kjaer, Lasse, Tolstrup, Janne S., Hasselbalch, Hans C., and Ellervik, Christina

Abstract

Meta‐analyses and Mendelian randomization (MR) may clarify the associations of smoking, blood cells and myeloproliferative neoplasms (MPN). We investigated the association of smoking with blood cells in the Danish General Suburban Population Study (GESUS, n = 11 083), by meta‐analyses (including GESUS) of 92 studies (n = 531 741) and MR of smoking variant CHRNA3 (rs1051730[A]) in UK Biobank, and with MPN in a meta‐analysis of six studies (n (total/cases):1 425 529/2187), totalling 2 307 745 participants. In the meta‐analysis the random‐effects standardized mean difference (SMD) in current smokers versus non‐smokers was 0·82 (0·75–0·89, P = 2·0 * 10−108) for leukocytes, 0·09 (−0·02 to 0·21, P = 0·12) for erythrocytes, 0·53 (0·42–0·64, P = 8·0 * 10−22) for haematocrit, 0·42 (0·34–0·51, P = 7·1 * 10−21) for haemoglobin, 0·19 (0·08–0·31, P = 1·2 * 10−3) for mean corpuscular haemoglobin (MCH), 0·29 (0·19–0·39, P = 1·6 * 10−8) for mean corpuscular volume (MCV), and 0·04 (−0·04 to 0·13, P = 0·34) for platelets with trends for ever/ex‐/current smokers, light/heavy smokers and female/male smokers. Analyses presented high heterogeneity but low publication bias. Per allele in CHRNA3, cigarettes per day in current smokers was associated with increased blood cell counts (leukocytes, neutrophils), MCH, red cell distribution width (RDW) and MCV. The pooled fixed‐effects odds ratio for MPN was 1·44 [95% confidence interval (CI): 1·33–1·56; P = 1·8 * 10−19; I2 = 0%] in current smokers, 1·29 (1·15–1·44; P = 8·0 * 10−6; I2 = 0%) in ex‐smokers, 1·49 (1·26–1·77; P = 4·4 * 10−6; I2 = 0%) in light smokers and 2·04 (1·74–2·39, P = 2·3 * 10−18; I2 = 51%) in heavy smokers compared with non‐smokers. Smoking is observationally and genetically associated with increased leukocyte counts and red blood cell indices (MCH, MCV, RDW) and observationally with risk of MPN in current and ex‐smokers versus non/never‐smokers.

Published
2020

47. Long-Term Use of Ropeginterferon Alpha-2b in Polycythemia Vera: 5-Year Results from a Randomized Controlled Study and Its Extension

Author

Gisslinger, Heinz, primary, Klade, Christoph, additional, Georgiev, Pencho, additional, Krochmalczyk, Dorota, additional, Gercheva-Kyuchukova, Liana, additional, Egyed, Miklos, additional, Dulicek, Petr, additional, Illés, Árpád, additional, Pylypenko, Halyna, additional, Sivcheva, Lylia, additional, Mayer, Jiří, additional, Yablokova, Vera, additional, Krejcy, Kurt, additional, Empson, Victoria, additional, Hasselbalch, Hans C., additional, Kralovics, Robert, additional, and Kiladjian, Jean Jacques, additional

Published
2020
Full Text
View/download PDF

48. Ropeginterferon Alfa-2b: Efficacy and Safety in Different Age Groups

Author

Gisslinger, Heinz, primary, Klade, Christoph, additional, Georgiev, Pencho, additional, Krochmalczyk, Dorota, additional, Gercheva-Kyuchukova, Liana, additional, Egyed, Miklos, additional, Rossiev, Viktor, additional, Dulicek, Petr, additional, Illes, Arpad, additional, Pylypenko, Halyna, additional, Sivcheva, Lylia, additional, Mayer, Jiri, additional, Yablokova, Vera, additional, Krejcy, Kurt, additional, Hasselbalch, Hans C., additional, Kralovics, Robert, additional, and Kiladjian, Jean-Jacques, additional

Published
2020
Full Text
View/download PDF

49. A phase II study of vorinostat (MK-0683) in patients with polycythaemia vera and essential thrombocythaemia

Author

Andersen, Christen L., McMullin, Mary F., Ejerblad, Elisabeth, Zweegman, Sonja, Harrison, Claire, Fernandes, Savio, Bareford, David, Knapper, Steven, Samuelsson, Jan, Löfvenberg, Eva, Linder, Olle, Andreasson, Bjrn, Ahlstrand, Erik, Jensen, Morten K., Bjerrum, Ole W., Vestergaard, Hanne, Larsen, Herdis, Klausen, Tobias W., Mourits-Andersen, Torben, and Hasselbalch, Hans C.

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results